Cosmo had profit in 2009 first half on demand for ulcerative colitis product

Cosmo Pharmaceuticals SpA booked a profit after tax of €2 million in the 2009 first half, after a year-earlier loss of € 0.8 million, as demand for Lialda/Mezavant (mesalazine), its treatment for ulcerative colitis, grew.